Perampanel Helped Many Children With New Epilepsy Stay Seizure-Free

What was studied

This study looked at perampanel, a seizure medicine, used as the first and only seizure medicine for children with epilepsy. It was a prospective observational study at one children's hospital in Shenzhen, China, from August 2021 to August 2023.

A total of 137 children started treatment. Two were lost to follow-up, and seven stopped perampanel because side effects were too hard to tolerate. The main results were based on 128 children who were retained in follow-up for up to 12 months. Their average age was about 8 years. The study tracked how many became seizure-free, how many had a meaningful drop in seizures, how many stayed on the medicine, and what side effects happened.

What they found

At 6 months, 75.0% of the 128 children were seizure-free, and at 12 months, 64.1% were seizure-free. The response rate, meaning children who had a clear improvement in seizures, was 92.9% at 6 months and 90.6% at 12 months.

Among 42 children with self-limited epilepsy with centrotemporal spikes (SeLECTS), 78.6% were seizure-free during the 12-month follow-up. In children without SeLECTS, the 12-month seizure-free rate was 56.9%.

Side effects were reported in 34 children, for an average rate of 24.8%. The most common were dizziness, drowsiness, and irritability. The authors said most side effects were mild and temporary, and some children were able to stay on treatment after slower dose increases or dose adjustment. Seven children stopped the medicine because of side effects.

The abstract also reported that patients receiving 4 mg/day had the highest seizure-free rate in this study.

Limits of the evidence

This was not a randomized trial, and there was no comparison group taking another seizure medicine or no treatment. Because of that, the study cannot show how perampanel compares with other first medicines.

It was done at a single center, so the results may not apply to all children with epilepsy. The sample size was modest, and some results, such as the finding that 4 mg/day had the highest seizure-free rate, may not hold up in other groups. The abstract also does not give detailed information about all epilepsy types, seizure types, or factors linked to better outcomes.

For families and caregivers

This study suggests that perampanel may work well as a first seizure medicine for some children, and many children in this group were seizure-free after 6 to 12 months. The results also suggest that side effects were fairly common but often mild.

For families, this may be useful as early real-world evidence that perampanel may be one option for childhood epilepsy. But it does not show that it is the best first choice for every child, and treatment decisions still depend on the child's epilepsy type, age, and side effect risks.

What to watch next

Larger studies, especially ones that directly compare perampanel with other first-line seizure medicines in children, would help clarify how it performs relative to other options.

Terms in this summary

perampanel

A seizure medicine used to help prevent seizures.

monotherapy

Treatment with just one medicine instead of a combination of medicines.

observational study

A study where researchers watch what happens in regular care without randomly assigning treatments.

seizure-free rate

The percentage of patients who had no seizures during a set period of follow-up.

response rate

The percentage of patients whose seizures improved by a meaningful amount.

adverse events

Side effects or unwanted problems that happen during treatment.

retention rate

The percentage of patients who stayed on the medicine over time.

SeLECTS

A common childhood epilepsy syndrome called self-limited epilepsy with centrotemporal spikes.